ELK Biotechnology

Recombinant Human IL-17A

Catalog #	EPT053
Expression Host	E.coli
DESCRIPTION	Recombinant Human Interleukin-17A is produced by our E.coli expression system and the target gene encoding Gly24-Ala155 is expressed.
Accession	Q16552
Synonyms	Interleukin-17A; IL-17; IL-17A; Cytotoxic T-Lymphocyte-Associated Antigen 8; CTLA-8; IL17A; CTLA8; IL17
Mol Mass	15.26 KDa
AP Mol Mass	16 KDa, reducing conditions
Purity	Greater than 95% as determined by reducing SDS-PAGE.
Endotoxin	Less than 0.1 ng/μg (1 EU/μg) as determined by LAL test.
FORMULATION	Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.
RECONSTITUTION	Always centrifuge tubes before opening.Do not mix by

+86-27-59760950 ELKbio@ELKbiotech.com www.elkbiotech.com

23-2, No.388 Gaoxin 2nd Road,Wuhan East Lake Hi-tech Development Zone, Hubei , P.R.C

vortex or pipetting.

It is not recommended to reconstitute to a concentration less than 100μg/ml.

Dissolve the lyophilized protein in distilled water.

Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

SHIPPING

The product is shipped at ambient temperature.

Upon receipt, store it immediately at the temperature listed below.

STORAGE

Lyophilized protein should be stored at < -20 ° C, though stable at room temperature for 3 weeks.

Reconstituted protein solution can be stored at 4-7°C for 2-7 days.

Aliquots of reconstituted samples are stable at < -20° C for 3 months.

BACKGROUND

Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis,

and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.

SDS-PAGE